Clinical trial
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress…
NCT00306670 · Georgetown University, Other · Terminated
Key facts
| NCT number | NCT00306670 |
|---|---|
| Title | Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A |
| Official title | A Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia A |
| Lead sponsor | Georgetown University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Rituxan, prednisone |
| Enrollment | 2 |
| Start date | Apr 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Mar 24, 2006 |
| Last update posted | Feb 10, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: